

ASX/Media Release

20 July 2016

Botanix Pharmaceuticals Secures Key Clinical and Manufacturing Staff

- Botanix Pharmaceuticals engages key clinical and manufacturing staff to drive acne development program
- Clinical leader with unique track record with synthetic cannabidiol and 30 years clinical experience
- Manufacturing leader has more than 35 years of manufacturing experience at leading dermatology companies

Perth, Australia; 20th July 2016: Medical dermatology company Botanix Pharmaceuticals (“Botanix” or “the Company”) today announced the engagement of two highly qualified global pharmaceutical industry executives to lead its development program for the Company’s lead acne program, BTX1503.

Mr Mark Davis has been engaged to lead the clinical and regulatory functions for Botanix together with Mr Steve Newhard to lead the manufacturing and quality functions for the Company.

Mr Davis has unique experience with synthetic cannabidiol, having led clinical activities for an epilepsy treatment program using this drug for Insys Inc, a US based pharmaceutical company. He has also held senior clinical and regulatory roles with two of the world’s largest dermatology companies, most recently with Medicis (sold to Valeant in 2012) and before that with Connectics which was acquired by Stiefel Laboratories (now a Pfizer company). Mr Davis has led development programs for the treatment of acne as well as other skin diseases that Botanix is pursuing with its pipeline of products.

Mr Newhard has 35 years’ experience in the quality operations, development, scale up and manufacturing of pharmaceutical products, having recently worked with Mr Davis at Medicis on a number of dermatology development programs. Mr Newhard will lead the formulation testing and clinical trial material manufacturing activities for Botanix in conjunction with the Company’s contract laboratory in Pennsylvania.

“We are very pleased to welcome both Mark and Steve to the team”, Botanix Executive Director Matt Callahan commented, “ both Mark and Steve bring highly relevant experience and technical knowledge to the program which will help accelerate development of BTX1503 for acne, as well as our pipeline products.”

“Very few people in the world have led the conduct of clinical trials involving cannabidiol, Mark’s experience in particular will guide our engagement with FDA and the Australian TGA as we move into clinical trials in early 2017.”

Botanix's engagement of Mr Davis and Mr Newhard follows its successful ASX debut on Friday 15 July 2016. Since listing, the Company's market capitalisation has increased by 92% from the capital raising price of \$0.02 and the Company's market capitalisation is currently \$15.5 million.

The Company plans to advance the first of its products for the treatment of acne into clinical trials in humans in Australia in 2017 and is actively exploring opportunities to leverage its skin delivery technology and growing team to rapidly advance other products into the clinic.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals is dedicated to developing next generation therapeutics for the treatment of serious skin diseases. Our mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed or are treated with therapeutics that are burdened with side effects profiles. Botanix is harnessing the untapped potential of a synthetic active pharmaceutical ingredient known as cannabidiol, which is currently being studied for the treatment of epilepsy, pain, arthritis and schizophrenia and has a well-established safety profile. Botanix is preparing for the first human trials with synthetic cannabidiol utilising a proprietary drug delivery system (Permetrex™) for direct skin delivery of the therapy.

For more information on Botanix, please visit www.botanixpharma.com or follow us on Twitter @Botanixpharma.

For more information, please contact:

General enquiries

Matt Callahan
Botanix Pharmaceuticals Inc
Executive Director
P: +1 215 767 4184
E: mcallahan@botanixpharma.com

Investor Relations

Rebecca Wilson
WE Buchan
P: 0417 382 391
E: rwilson@buchanwe.com.au

Media enquiries

Arthur Chan
WE Buchan
P: (02) 9237 2805
E: achan@buchanwe.com.au